StemCell Therapy

Public release date: 22-Jun-2012 [ | E-mail | Share ]

Contact: William Gilroy gilroy.6@nd.edu 574-631-4127 University of Notre Dame

Alumnus Michael Gallagher and his wife, Elizabeth, have made a $5 million gift to establish the Elizabeth and Michael Gallagher Family Professorships in Adult Stem Cell Research at the University of Notre Dame.

Their gift, which will fund three new endowed professorships in adult and all forms of non-embryonic stem cell research, will strengthen Notre Dame's leadership in the field of stem cell research and enhance the University's effective dialogue between the biomedical research community and the Catholic Church on matters related to the use and application of stem cells and regenerative medicine.

"As a Catholic university, Notre Dame carries a mantle of responsibility to use our scholarship and resources to help alleviate human suffering, and, in this area of research in particular, to do so with deep respect for the sanctity of all human life," said Rev. John I. Jenkins, C.S.C., the University's president. "These new professorships will enable us to effectively build upon an already strong foundation in this critically important field. We are tremendously grateful to the Gallaghers for making this possible with their transformative gift."

Despite years of research, there are no known cures for a large number of degenerative diseases, such as Type 1 diabetes, Parkinson's disease, cardiovascular disease, macular degeneration and spinal cord injuries. Stem cell research has the potential to contribute to the discovery of new and successful treatments for these and other diseases because it holds the unique promise of regenerating damaged cells and tissues, fully restoring tissues and organs to their normal function.

Although this vital area of research could accelerate the ability to alleviate much human suffering, it has generated extensive ethical debate with the use of embryonic versus non-embryonic stem cells. The Catholic Church affirms the dignity of all human life at every stage and vigorously opposes the destruction of human embryos for the harvesting of stem cells. At the same time, the Church strongly endorses the use of adult and non-embryonic stem cell research as a potential therapy for individuals suffering from these debilitating diseases. Research has demonstrated that adult stem cells, including all forms of non-embryonic stem cells, such as induced pluripotent stem cells and umbilical cord stem cells, can be harvested and programmed to achieve pluripotency the same characteristic that enables embryonic stem cells to differentiate into any type of cell.

An urgent need exists to increase the number of faculty experts performing adult stem cell research at Notre Dame. Doing so will expand upon the strong foundation the College of Science holds in these areas and will help create an environment for excellence in which faculty and students can learn, grow, collaborate and ultimately affect human health.

"We are overwhelmed with gratitude at the generous gift from Mike and Liz Gallagher," said Gregory P. Crawford, dean of the College of Science. "The impact of this gift is truly beyond measure. It will play a crucial role in attracting three more of the best faculty in the field of adult stem cell research to Notre Dame. Furthermore, this gift will equip our existing talented group of adult stem cell researchers at Notre Dame to take the next great leap toward ultimately forming a premier center in adult stem cell research."

Michael Gallagher is a 1991 graduate of Notre Dame, and his wife, Elizabeth, is a 1992 graduate of Saint Mary's College. They have two sons, Brock and Jack, and currently live near Denver.

Link:
Notre Dame establishes professorships in adult stem cell research

Stem cell therapy has gone to the dogs. The technology aimed at giving ailing pets a new lease on life has arrived in Hawaii.

13-year-old Kumba is still a bit dazed, coming out of general anesthesia. The veterinarian at Surf Paws Animal Hospital just extracted about two tablespoons of fat tissue from the dog. Stem cells from that fat tissue will then be used to help him with his arthritis.

"Once we get the stem cells then we do some extra processing steps to wake them up so that they're very active. At the end of that, the veterinarian will inject the stem cells into the areas of damage," says Carol Spangler Vaughn of Medivet America.

A company called MediVet America is bringing the technology to animal hospitals in Hawaii. This is a first for Oahu. The company says the procedure works on other animals with different types of ailments.

"So the nice thing about this we're not gonna give you a puppy back but we'll give you some nice quality time with your animal. You won't have to put them down because of their arthritis," Vaughn said.

Kumba's arthritis had gotten worse in the past five years, and his owners were wondering whether it was best to end his life to stop him from suffering.

'When we start saying things like oh we don't know how much longer, poor Kumba, he must be in a lot of pain. That kind of stuff really hits home especially since he's been with us for so long," said Rumi Hospodar Kumba's owner.

But with this new procedure, they're counting on Kumba to be pain free in a few weeks and are looking forward to get backdoing some of the things Kumba enjoyed, like swimming.

"He can't do that now since his joints are so bad, and he's getting so old so that's one of the many things I'm looking forward to," Kelsea Hopsodar, his other owner said.

The cost of the procedure runs from 24 to 28 hundred dollars, and it's covered by most pet insurance policies.

Follow this link:
Stem cell therapy gives dog new lease on life

HAWAII KAI (HawaiiNewsNow) -

Cutting-edge technology is helping Hawaii's pets live better lives for months, even years. We were there as a beloved dog named Kumba received one of the first-ever, in-clinic stem cell therapy surgeries in the islands.

13 year old Kumba doesn't know he's a guinea pig. The Rottweiler-Lab mix is one of the first in Hawaii to undergo the stem cell procedure at Surf Paws in Hawaii Kai.

Kumba suffers severe arthritis in his hips and knees, doesn't eat much, and is even a bit depressed. "It's an effort for him to get up off the floor, and when he gets up and crosses the room, you can see the stiffness," says his owner, Rumi Hospodar.

Kumba's kids learn some of details of his surgery. Then, he's moved to a table and nods off from anesthesia. Once he's prepped, the procedure begins. The vet removes about two tablespoons of fat tissue from Kumba's shoulder. From there, the stem cells are separated from the fat and activated. Then, they're injected back into the affected areas.

The entire process takes four hours, but the dog is actually only under for about 20 minutes. Surf Paws used to send the tissue to the mainland for processing, but with technology from Medi-Vet America, they can do it all here.

"The patient had to be, you know, go home and come back a few days later and the timing was a little bit difficult. Now, everything is same day," says Surf Paws veterinarian Dr. Cristina Miliaresis.

Cost depends on the size of animal but can run up to $2,800. It's mainly done on dogs, cats, and horses who suffer osteoarthritis, hip dysplasia, ligament and cartilage damage, and other degenerative diseases. Their quality of life can improve within a couple of weeks.

Dr. Miliaresis says, "Some people might say, 'Oh, the dog's 13. Why are you doing this for a 13 year old dog? But even 6 months, pain-free, after a very, it's not simple, but it's a pretty straightforward procedure, to me (would be) just amazing."

The techs move all 97 pounds of Kumba to post-op - while his anxious owner looks on.

Go here to read the rest:
Stem cell therapy in Hawaii going to the dogs

Have you ever wondered what happens to the stem cells once it is implanted in our body?

Well, now scientists had developed a method to track the stem cells in our body, according to a new report.

Scientists from the University of Liverpool have developed new methods to track stem cells and the changes that happen to them after they have been in the body for a significant period of time.

Scientists "labeled" the cells with superparamagnetic iron oxide nanoparticles (SPIONs) before they were administered to the patients.

The magnetic resonance imaging (MRI) scans clearly showed movement of the stem cells and the scientists could determine whether the stem cells reached their intended target or not.

However, scientists warn that conditions within the body's cells can lead to the degradation of SPIONs and reduce the ability of MRI scans to pick up on their signal in the long-term.

Like us on Facebook

To overcome this drawback, scientists are developing new methods to visualise SPION's in the cells before they enter the body to learn their performance in the long-term.

Photothermal technique, a unique optical imaging system is used to improve SPION labelling so that particles survive for longer and have minimal impact on the function of the transplanted cells.

"In order to fully explore this potential, however, more technological developments are needed to understand how stem cells behave in the body after transplantation. If we can't monitor stem cells effectively, it can have serious implications for patient health. Studies have already shown that if cells migrate to the circulatory system, beyond their target organ or tissue site, then it can cause inflammation in the body," said Dr Lara Bogart, scientist at the University's Institute of Integrative Biology in a statement.

Read the original here:
SPIONs to Track Functioning of Stem Cells Inside Body

On June 19 at noon, the Mississippi Sickle Cell Foundation will join millions around the world to commemorate World Sickle Cell Awareness Day. Courtesy Mississippi Sickle Cell Foundation

On June 19 at noon, the Mississippi Sickle Cell Foundation will join millions around the world to commemorate World Sickle Cell Awareness Day. MSCF will pray for patients with sickle cell disease and for families who have lost loved ones due to the illness. It encourages all Mississippians to join in an effort to bring awareness to the disease.

MSCF aims to educate Mississippians about the disease, encourage everyone to get tested for the trait and donate to sickle cell research. "In the past we've done vigils and balloon releases and that's great; but we really need people to be aware of the disease," MSCF Program Director Jefforey Stafford said. The MSCF reports there are currently at least 2,500 African Americans with the disease living in Mississippi.

The Centers for Disease Control reports that sickle cell disease affects approximately 90,000 to 100,000 Americans. The center estimates SCD occurs in 1 of every 500 black or African American births and in 1 of every 36,000 Hispanic American births. It is most commonly called sickle cell anemia.

In 2008, the United Nations deemed SCD a public health concern and declared June 19 as World Sickle Cell Day to bring awareness to the disease and its affects.

SCD is a hereditary disease of the red blood cells, which carry oxygen to all parts of the body. Here are a few facts about SCD:

People cannot catch it by being around someone who has it. The only cure is through a stem-cell or bone-marrow transplant. It can cause such problems as stroke, eye disease and severe infections. The goal of treatment is to relieve pain and prevent further complications.

For more information on how to assist MSCF visit http://www.mssicklecellfoundation.com or contact them at 601-366-5874.

Original post:
World Sickle Cell Day

Stem cell therapy has gone to the dogs. The technology aimed at giving ailing pets a new lease on life has arrived in Hawaii.

13-year-old Kumba is still a bit dazed, coming out of general anesthesia. The veterinarian at Surf Paws Animal Hospital just extracted about two tablespoons of fat tissue from the dog. Stem cells from that fat tissue will then be used to help him with his arthritis.

"Once we get the stem cells then we do some extra processing steps to wake them up so that they're very active. At the end of that, the veterinarian will inject the stem cells into the areas of damage," says Carol Spangler Vaughn of Medivet America.

A company called MediVet America is bringing the technology to animal hospitals in Hawaii. This is a first for Oahu. The company says the procedure works on other animals with different types of ailments.

"So the nice thing about this we're not gonna give you a puppy back but we'll give you some nice quality time with your animal. You won't have to put them down because of their arthritis," Vaughn said.

Kumba's arthritis had gotten worse in the past five years, and his owners were wondering whether it was best to end his life to stop him from suffering.

'When we start saying things like oh we don't know how much longer, poor Kumba, he must be in a lot of pain. That kind of stuff really hits home especially since he's been with us for so long," said Rumi Hospodar Kumba's owner.

But with this new procedure, they're counting on Kumba to be pain free in a few weeks and are looking forward to get backdoing some of the things Kumba enjoyed, like swimming.

"He can't do that now since his joints are so bad, and he's getting so old so that's one of the many things I'm looking forward to," Kelsea Hopsodar, his other owner said.

The cost of the procedure runs from 24 to 28 hundred dollars, and it's covered by most pet insurance policies.

See more here:
Stem cell therapy gives dog new lease on life

HAWAII KAI (HawaiiNewsNow) -

Cutting-edge technology is helping Hawaii's pets live better lives for months, even years. We were there as a beloved dog named Kumba received one of the first-ever, in-clinic stem cell therapy surgeries in the islands.

13 year old Kumba doesn't know he's a guinea pig. The Rottweiler-Lab mix is one of the first in Hawaii to undergo the stem cell procedure at Surf Paws in Hawaii Kai.

Kumba suffers severe arthritis in his hips and knees, doesn't eat much, and is even a bit depressed. "It's an effort for him to get up off the floor, and when he gets up and crosses the room, you can see the stiffness," says his owner, Rumi Hospodar.

Kumba's kids learn some of details of his surgery. Then, he's moved to a table and nods off from anesthesia. Once he's prepped, the procedure begins. The vet removes about two tablespoons of fat tissue from Kumba's shoulder. From there, the stem cells are separated from the fat and activated. Then, they're injected back into the affected areas.

The entire process takes four hours, but the dog is actually only under for about 20 minutes. Surf Paws used to send the tissue to the mainland for processing, but with technology from Medi-Vet America, they can do it all here.

"The patient had to be, you know, go home and come back a few days later and the timing was a little bit difficult. Now, everything is same day," says Surf Paws veterinarian Dr. Cristina Miliaresis.

Cost depends on the size of animal but can run up to $2,800. It's mainly done on dogs, cats, and horses who suffer osteoarthritis, hip dysplasia, ligament and cartilage damage, and other degenerative diseases. Their quality of life can improve within a couple of weeks.

Dr. Miliaresis says, "Some people might say, 'Oh, the dog's 13. Why are you doing this for a 13 year old dog? But even 6 months, pain-free, after a very, it's not simple, but it's a pretty straightforward procedure, to me (would be) just amazing."

The techs move all 97 pounds of Kumba to post-op - while his anxious owner looks on.

Go here to read the rest:
Stem cell therapy in Hawaii going to the dogs

Public release date: 21-Jun-2012 [ | E-mail | Share ]

Contact: Samantha Martin samantha.martin@liv.ac.uk 044-015-179-42248 University of Liverpool

Researchers at the University of Liverpool have developed new methods to track stem cells and further understanding of what happens to them after they have been in the body for a significant period of time.

Stem cells are used to treat conditions such as leukaemia and have the potential to treat many more diseases and disorders where patient survival is reliant on organ and tissue donation. Currently, however, it is difficult for medics to establish whether stem cells have survived following transplantation in the body and if they reach their target site or migrate elsewhere.

In order to track stem cells in the body scientists use superparamagnetic iron oxide nanoparticles (SPIONs) to 'label' the cells before they are administered into the patient. These particles can be picked up by magnetic resonance imaging (MRI) scans and help medics establish if the stem cells reach their intended target. Conditions within the body's cells, however, can lead to the degradation of SPIONs and reduce the ability of MRI scans to pick up on their signal in the long-term.

Scientists at Liverpool are developing methods to visualise SPIONs in the cells before they enter the body to learn where the particles are going within the stem cell and help predict how they might perform once they are inside the body over a long period of time. They are using a photothermal technique, a unique optical imaging system, to improve SPION labelling so that particles survive for longer and have minimal impact on the function of the transplanted cells.

Dr Lara Bogart, from the University's Institute of Integrative Biology, said: "Stem cells have the potential to replace and repair damaged tissue to preclude the need for a patient to wait for an organ or tissue transplant. Research is ongoing into how it could be used to treat a wide variety of diseases such as Alzheimer's, Parkinson's disease, and type one diabetes.

"In order to fully explore this potential, however, more technological developments are needed to understand how stem cells behave in the body after transplantation. If we can't monitor stem cells effectively, it can have serious implications for patient health. Studies have already shown that if cells migrate to the circulatory system, beyond their target organ or tissue site, then it can cause inflammation in the body.

"Labelling stem cells is hugely valuable to tracking their movements in the body, but we need to know more about how the particles used interact with stem cells. Using new imaging systems we can work out their precise location in the cell and how they behave over time. We hope to use this information to improve understanding of the MRI signal that tracks SPIONs once stem cells have been transplanted."

###

More:
Research could help track stem cells in the body

Researchers at the University of Liverpool have developed new methods to track stem cells and further understanding of what happens to them after they have been in the body for a significant period of time.

Stem cells are used to treat conditions such as leukaemia and have the potential to treat many more diseases and disorders where patient survival is reliant on organ and tissue donation. Currently, however, it is difficult for medics to establish whether stem cells have survived following transplantation in the body and if they reach their target site or migrate elsewhere.

In order to track stem cells in the body scientists use superparamagnetic iron oxide nanoparticles (SPIONs) to 'label' the cells before they are administered into the patient. These particles can be picked up by magnetic resonance imaging (MRI) scans and help medics establish if the stem cells reach their intended target. Conditions within the body's cells, however, can lead to the degradation of SPIONs and reduce the ability of MRI scans to pick up on their signal in the long-term.

Scientists at Liverpool are developing methods to visualise SPIONs in the cells before they enter the body to learn where the particles are going within the stem cell and help predict how they might perform once they are inside the body over a long period of time. They are using a photothermal technique, a unique optical imaging system, to improve SPION labelling so that particles survive for longer and have minimal impact on the function of the transplanted cells.

Dr Lara Bogart, from the University's Institute of Integrative Biology, said: "Stem cells have the potential to replace and repair damaged tissue to preclude the need for a patient to wait for an organ or tissue transplant. Research is ongoing into how it could be used to treat a wide variety of diseases such as Alzheimer's, Parkinson's disease, and type one diabetes.

"In order to fully explore this potential, however, more technological developments are needed to understand how stem cells behave in the body after transplantation. If we can't monitor stem cells effectively, it can have serious implications for patient health. Studies have already shown that if cells migrate to the circulatory system, beyond their target organ or tissue site, then it can cause inflammation in the body.

"Labelling stem cells is hugely valuable to tracking their movements in the body, but we need to know more about how the particles used interact with stem cells. Using new imaging systems we can work out their precise location in the cell and how they behave over time. We hope to use this information to improve understanding of the MRI signal that tracks SPIONs once stem cells have been transplanted."

More information: The research is published in the journal, ACS Nano.

Journal reference: ACS Nano

Provided by University of Liverpool

Read the original post:
Superparamagnetic iron oxide nanoparticles could help track stem cells in the body

NEWARK, Calif., June 21, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (STEM) today announced initiation of a Phase I/II clinical trial of the Company's proprietary HuCNS-SC(R) product candidate (purified human neural stem cells) in dry age-related macular degeneration (AMD) referred to as Geographic Atrophy. There are no approved treatments for dry AMD.

The trial is being conducted at the Retina Foundation of the Southwest's (RFSW) Anderson Vision Research Center in Dallas, Texas, one of the leading independent vision research centers in the United States. David G. Birch, Ph.D., Chief Scientific and Executive Officer of the RFSW and Director of the Rose-Silverthorne Retinal Degenerations Laboratory, is the principal investigator of the study.

"Dry AMD is the most common form of macular degeneration, and has a very debilitating effect on quality of life," said Dr. Birch. "Transplanting neural stem cells to protect photoreceptors in patients diagnosed with AMD is an innovative, but logical, approach, well supported by the Company's recently published preclinical data. We are very excited to be conducting this trial at RFSW."

A summary of the Company's preclinical data was featured in the February 2012 issue of the international peer-reviewed European Journal of Neuroscience (available online at http://onlinelibrary.wiley.com/doi/10.1111/j.1460-9568.2011.07970.x/abstract). The data demonstrated that HuCNS-SC cells protect host photoreceptors and preserve vision in the Royal College of Surgeons (RCS) rat, a well-established animal model of retinal disease which has been used extensively to evaluate potential cell therapies. Transplantation of HuCNS-SC cells significantly protects photoreceptors from degeneration. Moreover, the number of cone photoreceptors, which are responsible for central vision, remained constant over an extended period, consistent with the sustained visual acuity and light sensitivity observed in the study. In humans, degeneration of the cone photoreceptors accounts for the unique pattern of vision loss in dry AMD.

"Unlike others in the field, our clinical strategy is to preserve visual function before it is lost," said Stephen Huhn, MD, FACS, FAAP, Vice President and Head of the CNS Program at StemCells, Inc. "Our published preclinical data provides a strong rationale for this approach in dry AMD and we hope to replicate these results in this clinical trial. We are very pleased to be working with Dr. Birch and the Retina Foundation of the Southwest, who have the expertise and referral base to undertake this important study. We anticipate that we will be able to accrue the requisite number of patients for this trial in relatively short order."

About Age-Related Macular Degeneration

Age-related macular degeneration refers to a loss of photoreceptors (rods and cones) from the macula, the central part of the retina. AMD is a degenerative retinal disease that typically strikes adults in their 50s or early 60s, and progresses painlessly, gradually destroying central vision. According to the RFSW website, there are approximately 1.75 million Americans age 40 years and older with some form of age-related macular degeneration, and the disease continues to be the number one cause of irreversible vision loss among senior citizens in the US with more than seven million at risk of developing AMD.

About the Trial

The Phase I/II trial will evaluate the safety and preliminary efficacy of HuCNS-SC cells as a treatment for dry AMD. The trial will be an open-label, dose-escalation study, and is expected to enroll a total of 16 patients. The HuCNS-SC cells will be administered by a single injection into the space beneath the retina in the most affected eye. Patients' vision will be evaluated using both conventional and advanced state-of-the-art methods of ophthalmological assessment. Evaluations will be performed at predetermined intervals over a one-year period to assess safety and signs of visual benefit. Patients will then be followed for an additional four years in a separate observational study. Patients interested in participating in the clinical trial should contact the site at (214) 363 3911.

About HuCNS-SC Cells

Read the rest here:
StemCells, Inc. Initiates Phase I/II Clinical Trial in Dry Age-Related Macular Degeneration

ScienceDaily (June 21, 2012) Researchers at the University have developed new methods to track stem cells and further understanding of what happens to them after they have been in the body for a significant period of time.

Stem cells are used to treat conditions such as leukemia and have the potential to treat many more diseases and disorders where patient survival is reliant on organ and tissue donation. Currently, however, it is difficult for medics to establish whether stem cells have survived following transplantation in the body and if they reach their target site or migrate elsewhere.

In order to track stem cells in the body scientists use superparamagnetic iron oxide nanoparticles (SPIONs) to 'label' the cells before they are administered into the patient. These particles can be picked up by magnetic resonance imaging (MRI) scans and help medics establish if the stem cells reach their intended target. Conditions within the body's cells, however, can lead to the degradation of SPIONs and reduce the ability of MRI scans to pick up on their signal in the long-term.

Scientists at Liverpool are developing methods to visualise SPIONs in the cells before they enter the body to learn where the particles are going within the stem cell and help predict how they might perform once they are inside the body over a long period of time. They are using a photothermal technique, a unique optical imaging system, to improve SPION labelling so that particles survive for longer and have minimal impact on the function of the transplanted cells.

Effective monitoring

Dr Lara Bogart, from the University's Institute of Integrative Biology, said: "Stem cells have the potential to replace and repair damaged tissue to preclude the need for a patient to wait for an organ or tissue transplant. Research is ongoing into how it could be used to treat a wide variety of diseases such as Alzheimer's, Parkinson's disease, and type one diabetes.

"In order to fully explore this potential, however, more technological developments are needed to understand how stem cells behave in the body after transplantation. If we can't monitor stem cells effectively, it can have serious implications for patient health. Studies have already shown that if cells migrate to the circulatory system, beyond their target organ or tissue site, then it can cause inflammation in the body.

"Labelling stem cells is hugely valuable to tracking their movements in the body, but we need to know more about how the particles used interact with stem cells. Using new imaging systems we can work out their precise location in the cell and how they behave over time. We hope to use this information to improve understanding of the MRI signal that tracks SPIONs once stem cells have been transplanted."

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

Visit link:
Tracking stem cells in the body

June 21, 2012

Connie K. Ho for redOrbit.com

Pumping vigorously night and day, the heart is clearly one of the most important organs in the human body. It is also one of the most delicate parts of the body. As such, news regarding heart-related diseases is beneficial to both doctors and patients. University of Michigan (UM) researchers recently reported the discovery of a new method that could produce cardiac muscle patches from stem cells.

The innovative process was created at UMs Center for Arrhythmia Research and effectively uses stem cells that can copy the hearts squeezing action. The cells showed activity that was like that of peoples resting heart rate. The rhythmic electrical impulse transmission of the engineered cells worked at a rate of 60 beats per minute and this rate was 10 times quicker than rates reported in other stem cell studies.

To date, the majority of studies using induced pluripotent stem cell-derived cardiac muscle cells have focused on single cell functional analysis, remarked senior author Dr. Todd J. Herron, an assistant research professor in the Departments of Internal Medicine and Molecular & Integrative Physiology at the U-M, in a prepared statement.

The researchers believe that the stem biology findings will be beneficial to those who suffer from common but life-threatening heart diseases. They hope that the use of stem cells will assist patients diagnosed with arrhythmia, which is found in approximately 2.5 million people. With arrhythmia, patients suffer an irregularity in the hearts electrical impulses and this can hinder the hearts ability to circulate blood.

For potential stem cell-based cardiac regeneration therapies for heart disease, however, it is critical to develop multi-cellular tissue like constructs that beat as a single unit, commented Herron in the statement.

Regarding the specifics of the project, the goal of the scientists was to use stem cells to develop skin biopsies. These biopsies could be used to produce large quantities of cardiac muscle cells, which could then help transmit uniform electrical impulses and work as a cohesive unit. In collaborating with researchers from the University of Oxford, Imperial College, and the University of Wisconsin, the team was able to design a fluorescent imaging platform. The platform used light emitting diode (LED) illumination to quantify the cells electrical activity.

Action potential and calcium wave impulse propagation trigger each normal heart beat, so it is imperative to record each parameter in bioengineered human cardiac patches, remarked Herron in the statement.

Overall, authors of the study believe that the velocity of the engineered cardiac cells is still slower than the velocity of cells found in the beating adult heart. However, the velocity of the engineered cardiac cells is quicker than those previously reported; it is also similar to the rate found in commonly used rodent cells. For future scientific research purposes, the investigators theorize that human cardiac patches could be utilized instead of rodent systems. The new method could be used in many cardiac research laboratories and allow cardiac stem cell patches to be utilized in disease research, new drug treatment testing, and therapies focused on repairing damaged heart muscles.

Go here to see the original:
Stem Cells To Aid In Heart-Related Research

VILLA GUARDIA, Italy, June 21, 2012 (GLOBE NEWSWIRE) -- Gentium S.p.A. (GENT) (the "Company") announced today that it has submitted its responses to the Day 180 List of Outstanding Issues (the "LoOIs") received from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) with respect to the Company's Marketing Authorization Application (MAA) for Defibrotide to treat and prevent hepatic veno-occlusive disease (VOD) in adults and children undergoing haematopoietic stem cell transplantation therapy. Gentium expects to receive an opinion from the CHMP regarding the approval of Defibrotide during the third quarter of 2012.

"We are pleased that we have now submitted written responses to the CHMP's Day 180 LoOIs, bringing Defibrotide a step closer to a decision on our MAA," said Dr. Khalid Islam, Chairman and Chief Executive Officer of the Company.

If the written responses satisfy the questions raised in the LoOIs and the CHMP does not require any further explanation or clarification, a recommendation regarding the approval of Defibrotide could be issued by the CHMP as early as the third quarter of 2012. If additional oral explanations are required, a clock stop may be imposed. Based on the EMA review process timeline, the CHMP is expected to elicit a final opinion no later than Day 210.

About VOD

Veno-occlusive disease (VOD) is a potentially life-threatening condition, which typically occurs as a significant complication of stem cell transplantation. Certain high-dose conditioning regimens used as part of stem cell transplantation can damage the lining cells of hepatic blood vessels and result in VOD, a blockage of the small veins in the liver that leads to liver failure and can result in significant dysfunction in other organs such as the kidneys and lungs (so-called severe VOD). Stem cell transplantation is a frequently used treatment modality following high-dose chemotherapy and radiation therapy for hematologic cancers and other conditions in both adults and children. At present there is no approved agent for the treatment or prevention of VOD in the United States or the European Union.

About Gentium

Gentium S.p.A., located in Como, Italy, is a biopharmaceutical company focused on the development and manufacture of drugs to treat and prevent a variety of diseases and conditions, including vascular diseases related to cancer and cancer treatments. Defibrotide, the Company's lead product candidate, is an investigational drug that has been granted Orphan Drug status by the U.S. Food and Drug Administration (FDA) and Orphan Medicinal Product Designation by the European Medicines Agency, both to treat and to prevent VOD, as well as Fast Track Designation by the U.S. FDA to treat VOD.

The Gentium S.p.A. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=12669

Cautionary Note Regarding Forward-Looking Statements

This press release contains "forward-looking statements" that involve a number of risks and uncertainties the outcome of which could materially and/or adversely affect actual future results and the market price of Gentium's securities. In some cases, you can identify these statements by forward-looking words such as "may," "might," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," the negative of these terms and other comparable terminology. These statements are not historical facts but instead represent the Company's belief regarding future results, many of which, by their nature, are inherently uncertain and outside the Company's control. It is possible that actual results, including with respect to the possibility of any future regulatory approval, may differ materially from those anticipated in these forward-looking statements. Specifically, the risks and uncertainties that could affect the development of Defibrotide include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general, and with Defibrotide in particular, including, without limitation, the potential failure of Defibrotide to prove safe and effective for treatment and prevention of hepatic veno-occlusive disease (VOD) in adults and children undergoing haematopoietic stem cell transplantation, that Gentium may not receive an opinion regarding approval of Defibrotide from the CHMP in the third quarter of 2012, that the CHMP may request additional information from Gentium regarding Defibrotide, that Gentium may not receive a positive opinion from the CHMP, and the risk factors listed or described from time to time in Gentium's filings with the Securities and Exchange Commission including, without limitation, Gentium's most recent filings on Forms 20-F.

More:
Gentium Submits Day 180 Response to List of Outstanding Issues Received From the EMA's CHMP for Defibrotide MAA

ScienceDaily (June 21, 2012) A team of researchers led by UC Davis Health System has found that human alpha-defensin 6 (HD6) -- a key component of the body's innate defense system -- binds to microbial surfaces and forms "nanonets" that surround, entangle and disable microbes, preventing bacteria from attaching to or invading intestinal cells.

The research describes an entirely new mechanism of action for defensins, an important group of molecules known to bolster the defenses of circulating white blood cells, protect cellular borders from invasive pathogens and regulate which "friendly" microbes can colonize body surfaces. The discovery provides important clues to inflammatory bowel diseases, especially Crohn's disease, which may be caused, in part, by deficiencies in HD6 levels or function.

A paper describing the work appears in the June 22 issue of the journal Science.

"During the past 25 years, researchers have learned a lot about the biological function of defensins, but the role of HD6, a particular molecule that is highly expressed in the intestines, was a mystery," said Charles L. Bevins, professor of microbiology and immunology at UC Davis. "We now know that HD6 has a very unique role in the body's innate immune system. Its ability to latch onto microbial surfaces and self-assemble to cast a fibrous net around bacteria, including pathogens like Salmonella and Yersinia, as well as fungi and protozoan parasites, gives the intestine, a critical part of the body, a powerful and broad spectrum of defense against potential threats."

Bevins is co-senior author of the paper along with his UC Davis colleague Professor Andreas Bumler, an expert in bacterial pathogenesis; UCLA Emeritus Professor Robert I. Lehrer, whose laboratory was the first to discover defensins in the early 1980s; and Professor Wuyuan Lu, a synthetic protein chemist from the University of Maryland School of Medicine whose work provided clues to HD6's subtle and unique properties. First author Hiutung Chu, a graduate student in the Bevins lab who is now a fellow at the California Institute of Technology, was a driving force on the nine-year quest to solve the HD6 puzzle.

About the protein HD6

Defensins are a family of structurally related, small peptides with antibiotic activity found throughout nature in plants and animals. Humans make six different alpha-defensins. Two of these, HD5 and HD6, are secreted by Paneth cells, specialized secretory cells located within the folds of the small intestinal lining. HD5 has well-known antibacterial properties while the function of HD6 had been unknown. The defensin-rich secretions of Paneth cells work in conjunction with nearby intestinal stem cells to maintain micro flora balance and renew intestinal cellular surfaces.

Chu's graduate work focused on characterizing the biological activity of HD6 in studies using cultured intestinal epithelial cells and transgenic mouse models. Although Chu and Bevins anticipated HD6 activity would be very similar to other alpha-defensins, which kill pathogens by poking holes in the microbial membrane, their early research studies repeatedly showed that HD6 did not kill bacteria. Puzzled, they then looked for other possible functions, collaborating with UC Davis professors Angela Gelli and Scott Dawson to see if HD6 might kill only certain bacteria, fungi or parasites. It did not.

After two years into the project and feeling frustrated about the negative results, Bevins and Chu carefully reviewed the experimental data. That's when they recognized two crucial pieces of information. The first was that whenever HD6 was added to suspensions of either bacteria or fungi, a white haze, or precipitate, formed in the solution (see image below). The second was that early studies conducted in collaboration with Bumler had shown that while HD6 did not kill the bacterial pathogen Salmonella, it protected transgenic mice from an otherwise lethal infection.

"When we put these two results together, we were able to systematically show that HD6 was inhibiting microbial invasion and uncover HD6's unique structure and function at multiple levels," said Bevins.

Excerpt from:
Immune system molecule weaves cobweb-like nanonets to snag Salmonella, other intestinal microbes

Public release date: 20-Jun-2012 [ | E-mail | Share ]

Contact: Rod Dashwood rod.dashwood@oregonstate.edu 541-737-8101 Oregon State University

CORVALLIS, Ore. Researchers at Oregon State University for the first time have traced the actions of a known carcinogen in cooked meat to its complex biological effects on microRNA and cancer stem cells.

The findings are part of a growing awareness of the role of epigenetics in cancer, or the ways in which gene expression and cell behavior can be changed even though DNA sequence information is unaltered.

The scientists also found that consumption of spinach can partially offset the damaging effects of the carcinogen. In tests with laboratory animals, it cut the incidence of colon tumors almost in half, from 58 percent to 32 percent.

The research at OSU's Linus Pauling Institute was recently reported in the journal Molecular Nutrition and Food Research, in work supported by the National Institutes of Health.

"Cancer development is a complex, multi-step process, with damaged cells arising through various means," said Mansi Parasramka, a postdoctoral scholar with LPI. "This study showed that alterations of microRNAs affect cancer stem cell markers in colon cancer formation.

"MicroRNAs are very small factors that do very big things in cells," she said.

Traditionally, cancer was thought to be caused by changes in DNA sequence, or mutations, that allowed for uncontrolled cell growth. That's still true. However, there's also increasing interest in the role played by epigenetics, in which such factors as diet, environmental toxins, and lifestyle affect the expression of genes not just in cancer, but also cardiovascular disease, diabetes, and neurological disorders.

Included in this epigenetic equation is the formation of microRNAs once thought to be "junk DNA" - which researchers were at a loss to understand. It's now known that they influence which areas of DNA get expressed or silenced.

See the original post:
Study links carcinogens to cancer stem cells -- but spinach can help

ScienceDaily (June 20, 2012) Researchers at Oregon State University have for the first time traced the actions of a known carcinogen in cooked meat to its complex biological effects on microRNA and cancer stem cells.

The findings are part of a growing awareness of the role of epigenetics in cancer, or the ways in which gene expression and cell behavior can be changed even though DNA sequence information is unaltered.

The scientists also found that consumption of spinach can partially offset the damaging effects of the carcinogen. In tests with laboratory animals, it cut the incidence of colon tumors almost in half, from 58 percent to 32 percent.

The research at OSU's Linus Pauling Institute was recently reported in the journal Molecular Nutrition and Food Research, in work supported by the National Institutes of Health.

"Cancer development is a complex, multi-step process, with damaged cells arising through various means," said Mansi Parasramka, a postdoctoral scholar with LPI. "This study showed that alterations of microRNAs affect cancer stem cell markers in colon cancer formation.

"MicroRNAs are very small factors that do very big things in cells," she said.

Traditionally, cancer was thought to be caused by changes in DNA sequence, or mutations, that allowed for uncontrolled cell growth. That's still true. However, there's also increasing interest in the role played by epigenetics, in which such factors as diet, environmental toxins, and lifestyle affect the expression of genes -- not just in cancer, but also cardiovascular disease, diabetes, and neurological disorders.

Included in this epigenetic equation is the formation of microRNAs -- once thought to be "junk DNA" -- which researchers were at a loss to understand. It's now known that they influence which areas of DNA get expressed or silenced.

There are hundreds of microRNAs, and the OSU scientists monitored 679 in their experiments. When they don't work right, bad things can happen, including abnormal gene expression leading to cancer.

"Recent research is showing that microRNAs are one of the key epigenetic mechanisms regulating cellular functions in normal and diseased tissues," said Rod Dashwood, the Helen P. Rumbel Professor for Cancer Prevention and director of LPI's Cancer Chemoprotection Program.

Original post:
Carcinogens linked to cancer stem cells, but spinach can help

Newswise Johns Hopkins researchers have discovered that a single protein molecule may hold the key to turning cardiac stem cells into blood vessels or muscle tissue, a finding that may lead to better ways to treat heart attack patients.

Human heart tissue does not heal well after a heart attack, instead forming debilitating scars. For reasons not completely understood, however, stem cells can assist in this repair process by turning into the cells that make up healthy heart tissue, including heart muscle and blood vessels. Recently, doctors elsewhere have reported promising early results in the use of cardiac stem cells to curb the formation of unhealthy scar tissue after a heart attack. But the discovery of a master molecule that guides the destiny of these stem cells could result in even more effective treatments for heart patients, the Johns Hopkins researchers say.

In a study published in the June 5 online edition of the journal Science Signaling, the team reported that tinkering with a protein molecule called p190RhoGAP shaped the development of cardiac stem cells, prodding them to become the building blocks for either blood vessels or heart muscle. The team members said that by altering levels of this protein, they were able to affect the future of these stem cells.

In biology, finding a central regulator like this is like finding a pot of gold, said Andre Levchenko, a biomedical engineering professor and member of the Johns Hopkins Institute for Cell Engineering, who supervised the research effort.

The lead author of the journal article, Kshitiz, a postdoctoral fellow who uses only his first name, said, Our findings greatly enhance our understanding of stem cell biology and suggest innovative new ways to control the behavior of cardiac stem cells before and after they are transplanted into a patient. This discovery could significantly change the way stem cell therapy is administered in heart patients.

Earlier this year, a medical team at Cedars-Sinai Medical Center in Los Angeles reported initial success in reducing scar tissue in heart attack patients after harvesting some of the patients own cardiac stem cells, growing more of these cells in a lab and transfusing them back into the patient.

Using the stem cells from the patients own heart prevented the rejection problems that often occur when tissue is transplanted from another person.

Levchenkos team wanted to figure out what, at the molecular level, causes the stem cells to change into helpful heart tissue. If they could solve this mystery, the researchers hoped the cardiac stem cell technique used by the Los Angeles doctors could be altered to yield even better results.

During their research, the Johns Hopkins team members wondered whether changing the surface where the harvested stem cells grew would affect the cells development. The researchers were surprised to find that growing the cells on a surface whose rigidity resembled that of heart tissue caused the stem cells to grow faster and to form blood vessels. A cell population boom occurred far less often in the stem cells grown in the glass or plastic dishes typically used in biology labs. This result also suggested why formation of cardiac scar tissue, a structure with very different rigidity, can inhibit stem cells naturally residing there from regenerating the heart.

Looking further into this stem cell differentiation, the Johns Hopkins researchers found that the increased cell growth occurred when there was a decrease in the presence of the protein p190RhoGAP.

See the rest here:
'Master Molecule' May Improve Stem Cell Treatment of Heart Attacks

Scottish First Minister Alex Salmond is in California this week, knocking on the doors of disgruntled CEOS tired of high taxes, trying to lure them to expand research and manufacturing facilities to Scotland.

Top on the list of targets are businesses in the life sciences industry ---- which is a strong sector in San Diego County that has seen rapid growth and attracted millions of dollars in investment locally.

However, one of the first big deals to emerge from Salmond's visit may come in the renewable energy field ---- another strong area in San Diego County ---- following a meeting between Salmond and California Gov. Jerry Brown on Tuesday.

In a phone interview Wednesday, Salmond said that he and Brown agreed to have their staff look into drafting a memorandum of understanding that addresses how their two governments could share ---- or pursue ---- renewable energy research or manufacturing. One of the first avenues to pursue may be to form joint research work at the university level, Salmond said.

"Yes, we think the relations between Scotland and California could be a flourishing one," Salmond said. "We've set up a working party to look at potential cooperation in renewable energies."

The life sciences field is another area of interest to Salmond in Scotland, which gained international fame with the cloning of "Dolly" the sheep in the 1990s.

Dolly was the first mammal to be cloned from an adult cell by scientists at the Roslin Institute and the biotechnology company PPL Therapeutics, located near Edinburgh in Scotland.

Public relations statements distributed before Salmond's visit this week indicate that Scotland is ranked No. 1 in the world for stem-cell research, which is yet another field that San Diego County has gained high marks globally.

Of interest to Salmond is Carlsbad-based Life Technologies Corp., a biotechnology and medical instrumentation company that employs about 370 workers at a manufacturing and distribution facility in Paisley, located in the west central Lowlands area of Scotland.

"We have not made any further announcements in reference to what our plans are there," said Patty Zamora, a spokeswoman with Life Technologies.

Read this article:
ECONOMY: Scottish First Minister tries to lure California businesses overseas

ScienceDaily (June 20, 2012) Cedars-Sinai's Regenerative Medicine Institute has pioneered research on how motor-neuron cell-death occurs in patients with spinal muscular atrophy, offering an important clue in identifying potential medicines to treat this leading genetic cause of death in infants and toddlers.

The study, published in the June 19 online issue of PLoS ONE, extends the institute's work to employ pluripotent stem cells to find a pharmaceutical treatment for spinal muscular atrophy or SMA, a genetic neuromuscular disease characterized by muscle atrophy and weakness.

"With this new understanding of how motor neurons die in spinal muscular atrophy patients, we are an important step closer to identifying drugs that may reverse or prevent that process," said Clive Svendsen, PhD, director of the Cedars-Sinai Regenerative Medicine Institute.

Svendsen and his team have investigated this disease for some time now. In 2009, Nature published a study by Svendsen and his colleagues detailing how skin cells taken from a patient with the disorder were used to generate neurons of the same genetic makeup and characteristics of those affected in the disorder; this created a "disease-in-a-dish" that could serve as a model for discovering new drugs.

As the disease is unique to humans, previous methods to employ this approach had been unreliable in predicting how it occurs in humans. In the research published in PLoS ONE, the team reproduced this model with skin cells from multiple patients, taking them back in time to a pluripotent stem cell state (iPS cells), and then driving them forward to study the diseased patient-specific motor neurons.

Children born with this disorder have a genetic mutation that doesn't allow their motor neurons to manufacture a critical protein necessary for them to survive. The study found these cells die through apoptosis -- the same form of cell death that occurs when the body eliminates old, unnecessary as well as unhealthy cells. As motor neuron cell death progresses, children with the disease experience increasing paralysis and eventually death. There is no effective treatment now for this disease. An estimated one in 35 to one in 60 people are carriers and about in 100,000 newborns have the condition.

"Now we are taking these motor neurons (from multiple children with the disease and in their pluripotent state) and screening compounds that can rescue these cells and create the protein necessary for them to survive," said Dhruv Sareen, director of Cedars-Sinai's Induced Pluripotent Stem Cell Core Facility and a primary author on the study. "This study is an important stepping stone to guide us toward the right kinds of compounds that we hope will be effective in the model -- and then be reproduced in clinical trials."

The study was funded in part by a $1.9 million Tools and Technology grant from the California Institute for Regenerative Medicine aimed at developing new tools and technologies to aid pharmaceutical discoveries for this disease.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

More:
Understanding of spinal muscular atrophy improved with use of stem cells

The leading international family stem cell bank, Cryo-Save, celebrates the grand opening of its brand new headquarters office in Zutphen, the Netherlands, by honoring PhD. T.H.J. Nijhuis with the Young Investigator Award on June 22nd.

Cryo-Save`s headquarters, located in Zutphen, the Netherlands, is celebrating the grand opening of its brand new, fully-renovated headquarters. On June 22nd, Arnoud van Tulder, CEO of Cryo-Save, and attorney-at-law C. Bieze, deputy in the province of Gelderland, will officially open the company`s new global headquarters office.

To mark the occasion, the company will grant PhD. T.H.J. Nijhuis, winner of the Cryo-Save Young Investigator Award, a prize of 5,000 euros. Mr. Nijhuis has focused his most recent research on umbilical cord mesenchymal stem cells and pursues his work at the Erasmus Medical Center, part of the Erasmus University of Rotterdam, the Netherlands.

Arnoud van Tulder, CEO of Cryo-Save, says "We are proud to name Mr. T.H.J. Nijhuis, as the winner of the Cryo-Save Young Investigator Award. Research is a cornerstone of the stem cell industry, and it`s advancements like that of Mr. T.H.J. Nijhuis that makes us so optimistic for the future."

As part of Cryo-Save`s educational and community outreach efforts, the Cryo-Save Young Investigator Award is yet another example of how the company supports the advancement of stem cell use in the medical field. Cryo-Save seeks to improve and expand stem cell knowledge among the general public and professional health community, as they see in stem cell therapy a huge potential in the treatment of various diseases.

More information:

Ccile Kastler - Communications Manager

cecile.kastler@cryo-save.com - tel. +41-(0) 79 827 80 98

Cryo-Save: http://www.cryo-save.com/group

Cryo-Save, the leading international family stem cell bank, stores more than 200,000 samples from umbilical cord blood, cord tissue and adipose tissue. There are already many diseases treatable by the use of stem cells, and the number of treatments will only increase. Driven by its international business strategy, Cryo-Save is now represented in over 40 countries on 3 continents, with ultra-modern processing and storage facilities in Belgium, Germany, Dubai, India and South Africa.

Read this article:
Cryo-Save Group N.V. awards researcher at grand opening of its new headquarters